Overview
NMDA receptor antibodies are autoantibodies directed against subunits of the N-methyl-D-aspartate receptor, a glutamate receptor that plays a central role in synaptic transmission, plasticity, learning, and memory. Antibodies against the NR1 subunit are classically associated with autoimmune anti-NMDAR encephalitis, while antibodies against NR2 subunits may be seen in limbic encephalitis, systemic lupus erythematosus, ataxia, and epilepsia partialis continua. The condition predominantly affects children, adolescents, and young adults and is more common in females, although males may also be affected. In some cases, the disorder is associated with underlying tumors, most commonly ovarian teratomas.
Symptoms
Patients with NMDA receptor antibody-associated disease typically present with prominent neuropsychiatric features. Early symptoms often include behavioral changes, anxiety, psychosis, hallucinations, agitation, and memory impairment, which may be misdiagnosed as primary psychiatric illness. As the disease progresses, patients may develop seizures, speech dysfunction, movement disorders such as dyskinesias or rigidity, autonomic instability with fluctuations in blood pressure, heart rate, and temperature, and decreased level of consciousness. Adults more commonly present with psychiatric symptoms, whereas children often present with seizures and abnormal movements.
Causes
NMDA receptor antibody-mediated encephalitis is caused by an autoimmune response in which IgG antibodies bind to NMDA receptors on neuronal surfaces. This binding leads to receptor internalization and reduced glutamate signaling, resulting in synaptic dysfunction and widespread neuropsychiatric manifestations. The autoimmune process may occur with or without an associated tumor. Tumor-related immune activation, particularly from ovarian teratomas containing neural tissue, is thought to trigger antibody production in some patients. In other cases, the trigger remains unknown.
Risk Factors
Risk factors include young age, female sex, and the presence of tumors such as ovarian teratomas. Patients with unexplained acute or subacute onset of psychosis, seizures, or encephalopathy are at increased risk of this diagnosis. Individuals with autoimmune diseases or post-infectious neurological syndromes may also be susceptible. Interpretation of test results requires caution, as serum testing may be negative in a subset of patients despite positive cerebrospinal fluid findings. Older patients may present with atypical phenotypes, making diagnosis more challenging.
Prevention
There are no established preventive measures for NMDA receptor antibody-associated encephalitis. Prevention in a clinical context focuses on early recognition, appropriate antibody testing, and timely treatment. Proper sample collection of serum and cerebrospinal fluid and the use of sensitive detection methods support accurate diagnosis. Serial measurement of antibody titers helps monitor treatment response and detect relapse. Early identification and management significantly improve outcomes and reduce long term neurological and psychiatric complications associated with this autoimmune condition.
